vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($962.7M vs $493.8M, roughly 1.9× Pediatrix Medical Group, Inc.). APTARGROUP, INC. runs the higher net margin — 7.7% vs 6.8%, a 0.9% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (13.5% vs -1.7%). Over the past eight quarters, APTARGROUP, INC.'s revenue compounded faster (2.6% CAGR vs -0.1%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
ATR vs MD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $962.7M | $493.8M |
| Net Profit | $74.3M | $33.7M |
| Gross Margin | — | — |
| Operating Margin | 11.0% | 9.9% |
| Net Margin | 7.7% | 6.8% |
| Revenue YoY | 13.5% | -1.7% |
| Net Profit YoY | -26.4% | 10.5% |
| EPS (diluted) | $1.13 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $962.7M | $493.8M | ||
| Q3 25 | $961.1M | $492.9M | ||
| Q2 25 | $966.0M | $468.8M | ||
| Q1 25 | $887.3M | $458.4M | ||
| Q4 24 | $848.1M | $502.4M | ||
| Q3 24 | $909.3M | $511.2M | ||
| Q2 24 | $910.1M | $504.3M | ||
| Q1 24 | $915.4M | $495.1M |
| Q4 25 | $74.3M | $33.7M | ||
| Q3 25 | $127.9M | $71.7M | ||
| Q2 25 | $111.7M | $39.3M | ||
| Q1 25 | $78.8M | $20.7M | ||
| Q4 24 | $100.9M | $30.5M | ||
| Q3 24 | $100.0M | $19.4M | ||
| Q2 24 | $90.5M | $-153.0M | ||
| Q1 24 | $83.1M | $4.0M |
| Q4 25 | 11.0% | 9.9% | ||
| Q3 25 | 14.2% | 13.8% | ||
| Q2 25 | 14.9% | 12.8% | ||
| Q1 25 | 12.8% | 7.0% | ||
| Q4 24 | 14.2% | 7.8% | ||
| Q3 24 | 15.2% | 6.6% | ||
| Q2 24 | 13.8% | -31.3% | ||
| Q1 24 | 12.2% | 3.2% |
| Q4 25 | 7.7% | 6.8% | ||
| Q3 25 | 13.3% | 14.5% | ||
| Q2 25 | 11.6% | 8.4% | ||
| Q1 25 | 8.9% | 4.5% | ||
| Q4 24 | 11.9% | 6.1% | ||
| Q3 24 | 11.0% | 3.8% | ||
| Q2 24 | 9.9% | -30.3% | ||
| Q1 24 | 9.1% | 0.8% |
| Q4 25 | $1.13 | $0.40 | ||
| Q3 25 | $1.92 | $0.84 | ||
| Q2 25 | $1.67 | $0.46 | ||
| Q1 25 | $1.17 | $0.24 | ||
| Q4 24 | $1.48 | $0.37 | ||
| Q3 24 | $1.48 | $0.23 | ||
| Q2 24 | $1.34 | $-1.84 | ||
| Q1 24 | $1.23 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $409.5M | $375.2M |
| Total DebtLower is stronger | $1.1B | $570.5M |
| Stockholders' EquityBook value | $2.7B | $865.9M |
| Total Assets | $5.3B | $2.2B |
| Debt / EquityLower = less leverage | 0.43× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $409.5M | $375.2M | ||
| Q3 25 | $264.8M | $340.1M | ||
| Q2 25 | $169.8M | $224.7M | ||
| Q1 25 | $136.8M | $99.0M | ||
| Q4 24 | $226.2M | $229.9M | ||
| Q3 24 | $327.9M | $103.8M | ||
| Q2 24 | $223.9M | $19.4M | ||
| Q1 24 | $201.1M | $8.0M |
| Q4 25 | $1.1B | $570.5M | ||
| Q3 25 | $546.0M | $577.2M | ||
| Q2 25 | $535.1M | $583.9M | ||
| Q1 25 | $561.2M | $590.5M | ||
| Q4 24 | $688.1M | $597.1M | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — | ||
| Q1 24 | $680.4M | — |
| Q4 25 | $2.7B | $865.9M | ||
| Q3 25 | $2.8B | $890.7M | ||
| Q2 25 | $2.7B | $833.8M | ||
| Q1 25 | $2.5B | $789.2M | ||
| Q4 24 | $2.5B | $764.9M | ||
| Q3 24 | $2.5B | $732.5M | ||
| Q2 24 | $2.4B | $706.5M | ||
| Q1 24 | $2.3B | $856.2M |
| Q4 25 | $5.3B | $2.2B | ||
| Q3 25 | $5.1B | $2.2B | ||
| Q2 25 | $4.9B | $2.1B | ||
| Q1 25 | $4.5B | $2.0B | ||
| Q4 24 | $4.4B | $2.2B | ||
| Q3 24 | $4.6B | $2.1B | ||
| Q2 24 | $4.5B | $2.0B | ||
| Q1 24 | $4.4B | $2.2B |
| Q4 25 | 0.43× | 0.66× | ||
| Q3 25 | 0.20× | 0.65× | ||
| Q2 25 | 0.20× | 0.70× | ||
| Q1 25 | 0.22× | 0.75× | ||
| Q4 24 | 0.28× | 0.78× | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.7M | $114.1M |
| Free Cash FlowOCF − Capex | $96.9M | — |
| FCF MarginFCF / Revenue | 10.1% | — |
| Capex IntensityCapex / Revenue | 9.0% | — |
| Cash ConversionOCF / Net Profit | 2.47× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $299.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.7M | $114.1M | ||
| Q3 25 | $177.6M | $137.3M | ||
| Q2 25 | $126.0M | $137.2M | ||
| Q1 25 | $82.7M | $-117.5M | ||
| Q4 24 | $178.2M | $133.0M | ||
| Q3 24 | $229.3M | $91.8M | ||
| Q2 24 | $143.6M | $107.0M | ||
| Q1 24 | $92.3M | $-125.2M |
| Q4 25 | $96.9M | — | ||
| Q3 25 | $114.3M | — | ||
| Q2 25 | $62.5M | — | ||
| Q1 25 | $25.9M | — | ||
| Q4 24 | $112.2M | — | ||
| Q3 24 | $162.7M | — | ||
| Q2 24 | $75.4M | — | ||
| Q1 24 | $16.7M | — |
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 1.8% | — |
| Q4 25 | 9.0% | — | ||
| Q3 25 | 6.6% | — | ||
| Q2 25 | 6.6% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 7.3% | — | ||
| Q2 24 | 7.5% | — | ||
| Q1 24 | 8.3% | — |
| Q4 25 | 2.47× | 3.39× | ||
| Q3 25 | 1.39× | 1.91× | ||
| Q2 25 | 1.13× | 3.49× | ||
| Q1 25 | 1.05× | -5.66× | ||
| Q4 24 | 1.77× | 4.36× | ||
| Q3 24 | 2.29× | 4.72× | ||
| Q2 24 | 1.59× | — | ||
| Q1 24 | 1.11× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
| Pharma Segment | $833.1M | 87% |
| Other | $129.6M | 13% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
